Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (64)

III-01Stefanie Kraff

Excel®-Based Tools for Pharmacokinetically Guided Dose Adjustment of Paclitaxel and Docetaxel

Thursday 10:05-11:35

III-02Andreas Krause

Modeling the two peak phenomenon in pharmacokinetics using a gut passage model with two absorption sites

Thursday 10:05-11:35

III-03Elke Krekels

Item response theory for the analysis of the placebo effect in Phase 3 studies of schizophrenia

Thursday 10:05-11:35

III-04Anders Kristoffersson

Inter Occasion Variability (IOV) in Individual Optimal Design (OD)

Thursday 10:05-11:35

III-05Cédric Laouenan

Modelling early viral hepatitis C kinetics in compensated cirrhotic treatment-experienced patients treated with triple therapy including telaprevir or boceprevir

Thursday 10:05-11:35

III-06Anna Largajolli

An integrated glucose-insulin minimal model for IVGTT

Thursday 10:05-11:35

III-07Robert Leary

A Fast Bootstrap Method Using EM Posteriors

Thursday 10:05-11:35

III-08Donghwan Lee

Development of a Disease Progression Model in Korean Patients with Type 2 Diabetes Mellitus(T2DM)

Thursday 10:05-11:35

III-09Joomi Lee

Population pharmacokinetics of prothionamide in Korean tuberculosis patients

Thursday 10:05-11:35

III-10

Modeling Targeted Therapies in Oncology: Incorporation of Cell-cycle into a Tumor Growth Inhibition Model

Thursday 10:05-11:35

III-11Tarek Leil

PK-PD Modeling using 4β-Hydroxycholesterol to Predict CYP3A Mediated Drug Interactions

Thursday 10:05-11:35

III-12Annabelle Lemenuel Diot

How to improve the prediction of Sustained Virologic Response (SVR) for Hepatitis C patients using early Viral Load (VL) Information

Thursday 10:05-11:35

III-13Joanna Lewis

A homeostatic model for CD4 count recovery in HIV-infected children

Thursday 10:05-11:35

III-14Yan Li

Modeling and Simulation to Probe the Likely Difference in Pharmacokinetic Disposition of R- and S-Enantiomers Justifying the Development of Racemate Pomalidomide

Thursday 10:05-11:35

III-15Lia Liefaard

Predicting levels of pharmacological response in long-term patient trials based on short-term dosing PK and biomarker data from healthy subjects

Thursday 10:05-11:35

III-16Karl-Heinz Liesenfeld

Pharmacometric Characterization of the Elimination of Dabigatran by Haemodialysis

Thursday 10:05-11:35

III-17

Model-based QTc interval risk assessment in Phase 1 studies and its impact on the drug development trajectory

Thursday 10:05-11:35

III-18Hyeong-Seok Lim

Pharmacokinetics of S-1, an Oral 5-Fluorouracil Agent in Patients with Gastric Surgery

Thursday 10:05-11:35

III-19Andreas Lindauer

Comparison of NONMEM Estimation Methods in the Application of a Markov-Model for Analyzing Sleep Data

Thursday 10:05-11:35

III-20

Simulations to investigate new Intermittent Preventive Therapy Dosing Regimens for Dihydroartemisinin-Piperaquine

Thursday 10:05-11:35

III-21Dan Lu

Semi-mechanistic Multiple-analyte Population Model of Antibody-drug-conjugate Pharmacokinetics

Thursday 10:05-11:35

III-22Viera Lukacova

Physiologically Based Pharmacokinetic (PBPK) Modeling of Amoxicillin in Neonates and Infants

Thursday 10:05-11:35

III-23Panos Macheras

On the Properties of a Two-Stage Design for Bioequivalence Studies

Thursday 10:05-11:35

III-24

Using modelling and simulation to evaluate potential drug repositioning to a new therapy area

Thursday 10:05-11:35

III-25Paolo Magni

A PK-PD model of tumor growth after administration of an anti-angiogenic agent given alone or in combination therapies in xenograft mice

Thursday 10:05-11:35

III-26Mathilde Marchand

Population Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Daratumumab in Multiple Myeloma Patients

Thursday 10:05-11:35

III-27Eleonora Marostica

Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies

Thursday 10:05-11:35

III-28Hafedh Marouani

Dosage regimen individualization of the once-daily amikacin treatment by using kinetics nomograms.

Thursday 10:05-11:35

III-29Amelie Marsot

Population pharmacokinetics of baclofen in alcohol dependent patients

Thursday 10:05-11:35

III-30María Isabel Mas Fuster

Stochastic Simulations Assist to Select the Intravenous Digoxin Dosing Protocol in Elderly Patients in Acute Atrial Fibrillation

Thursday 10:05-11:35

III-31

Modeling tumor dynamics and overall survival in patients with low-grade gliomas treated with temozolomide.

Thursday 10:05-11:35

III-32Litaty Céphanoée Mbatchi

A PK-PGx study of irinotecan: influence of genetic polymorphisms of xenoreceptors CAR (NR1I3) and PXR (NR1I2) on PK parameters

Thursday 10:05-11:35

III-33

Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastro-esophageal reflux disease in children aged 1-11 years

Thursday 10:05-11:35

III-34Christophe Meille

Modeling of Erlotinib Effect on Cell Growth Measured by in vitro Impedance-based Real-Time Cell Analysis

Thursday 10:05-11:35

III-35

Characterizing the dose-efficacy relationship for anti-cancer drugs using longitudinal solid tumor modeling

Thursday 10:05-11:35

III-36Enrica Mezzalana

A Target-Mediated Drug Disposition model integrated with a T lymphocyte pharmacodynamic model for Otelixizumab.

Thursday 10:05-11:35

III-37Iris Minichmayr

A Microdialysate-based Integrated Model with Nonlinear Elimination for Determining Plasma and Tissue Pharmacokinetics of Linezolid in Four Distinct Populations

Thursday 10:05-11:35

III-38

Chronobiology of the Renin-Angiotensin-Aldosterone System (RAAS) in Dogs: Relation to Blood Pressure and Renal Physiology

Thursday 10:05-11:35

III-39Dirk Jan Moes

Evaluating the effect of CYP3A4 and CYP3A5 polymorphisms on cyclosporine, everolimus and tacrolimus pharmacokinetics in renal transplantation patients.

Thursday 10:05-11:35

III-40

Mixed Effects Modeling to Quantify the Effect of Empagliflozin Exposure on the Renal Glucose Threshold in Patients with Type 2 Diabetes Mellitus

Thursday 10:05-11:35

III-41Morris Muliaditan

Model-based evaluation of iron overload in patients affected by transfusion dependent diseases

Thursday 10:05-11:35

III-42Flora Musuamba-Tshinanu

Modelling of disease progression and drug effects in preclinical models of neuropathic pain

Thursday 10:05-11:35

III-43Kiyohiko Nakai

Urinary C-terminal Telopeptide of Type-I Collagen Concentration (uCTx) as a Possible Biomarker for Osteoporosis Treatment; A Direct Comparison of the Modeling and Simulation (M&S) Data and those Actually Obtained in Japanese Patients with Osteoporosis Following a Three-year-treatment with Ibandronic Acid (IBN)

Thursday 10:05-11:35

III-44Thu Thuy Nguyen

Mechanistic Model to Characterize and Predict Fecal Excretion of Ciprofloxacin Resistant Enterobacteria with Various Dosage Regimens

Thursday 10:05-11:35

III-45Tram Nguyen

Influence of a priori information, designs and undetectable data on individual parameters estimation and prediction of hepatitis C treatment outcome

Thursday 10:05-11:35

III-46Xavier Nicolas

Steady-state achievement and accumulation for a compound with bi-phasic disposition and long terminal half-life, estimation by different techniques

Thursday 10:05-11:35

III-47Ronald Niebecker

Are datasets for NLME models large enough for a bootstrap to provide reliable parameter uncertainty distributions?

Thursday 10:05-11:35

III-48Lisa O'Brien

Implementation of a Global NONMEM Modeling Environment

Thursday 10:05-11:35

III-49Kayode Ogungbenro

A physiological based pharmacokinetic model for low dose methotrexate in humans

Thursday 10:05-11:35

III-50Jaeseong Oh

A Population Pharmacokinetic-Pharmacodynamic Analysis of Fimasartan in Patients with Mild to Moderate Essential Hypertension

Thursday 10:05-11:35

III-51Fredrik Öhrn

Longitudinal Modelling of FEV1 Effect of Bronchodilators

Thursday 10:05-11:35

III-52Andrés Olivares-Morales

Qualitative prediction of human oral bioavailability from animal oral bioavailability data employing ROC analysis

Thursday 10:05-11:35

III-53Erik Olofsen

Simultaneous stochastic modeling of pharmacokinetic and pharmacodynamic data with noncoinciding sampling times

Thursday 10:05-11:35

III-54Sean Oosterholt

PKPD modelling of PGE2 inhibition and dose selection of a novel COX-2 inhibitor in humans.

Thursday 10:05-11:35

III-55Ignacio Ortega

Application of allometric techniques to predict F10503LO1 PK parameters in human

Thursday 10:05-11:35

III-56

Population pharmacokinetic model of sildenafil describing first-pass effect to its metabolite

Thursday 10:05-11:35

III-57Sung Min Park

Population pharmacokinetic/pharmacodynamic modeling for transformed binary effect data of triflusal in healthy Korean male volunteers

Thursday 10:05-11:35

III-58Zinnia Parra-Guillen

Population semi-mechanistic modelling of tumour response elicited by Immune-stimulatory based therapeutics in mice

Thursday 10:05-11:35

III-59Ines Paule

Population pharmacokinetics of an experimental drug’s oral modified release formulation in healthy volunteers, quantification of sensitivity to types and timings of meals.

Thursday 10:05-11:35

III-60Sophie Peigné

Paediatric Pharmacokinetic methodologies: Evaluation and comparison

Thursday 10:05-11:35

III-61Nathalie Perdaems

A semi-mechanistic PBPK model to predict blood, cerebrospinal fluid and brain concentrations of a compound in mouse, rat, monkey and human.

Thursday 10:05-11:35

III-62Chiara Piana

Optimal sampling and model-based dosing algorithm for busulfan in bone marrow transplantation patients.

Thursday 10:05-11:35

III-63Sebastian Polak

Pharmacokinetic (PK) and pharmacodynamic (PD) implications of diurnal variation of gastric emptying and small intestinal transit time for quinidine: A mechanistic simulation.

Thursday 10:05-11:35

III-64Angelica Quartino

Evaluation of Tumor Size Metrics to Predict Survival in Advanced Gastric Cancer

Thursday 10:05-11:35